BCRX — BioCryst Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.39bn
- $1.86bn
- $450.71m
- 30
- 38
- 42
- 28
Annual cashflow statement for BioCryst Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -183 | -184 | -247 | -227 | -88.9 |
| Depreciation | |||||
| Non-Cash Items | 20.1 | 33 | 143 | 162 | 123 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 26.9 | 8.12 | -58.9 | -32.4 | -87.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -135 | -142 | -162 | -95.1 | -52 |
| Capital Expenditures | -0.514 | -2.38 | -1.35 | -2.17 | -1.12 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -6.34 | 18.2 | -127 | -129 | 53.7 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -6.86 | 15.8 | -128 | -131 | 52.6 |
| Financing Cash Flow Items | — | — | — | -34.6 | -7.54 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 301 | 360 | 88 | 32.5 | -5.76 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 159 | 233 | -201 | -194 | -6.12 |